Gil Blum's Stock Ratings

Needham Analyst

Gil Blum is an analyst at Needham. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 03/03/2025

Overall Average Return

-2.02%

Smart Score

53.5%

Overall Average Return Percentile

32nd

Number of Ratings

388
Data brought to you by Benzinga APIs

Recent Analyst Stock Rating News

Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says
Recursion Pharmaceuticals is a leader in TechBio with potential to bring in $200M in near-term milestones and $20B in future revenue, according to Needham.
8 Analysts Have This To Say About Sarepta Therapeutics
What Analysts Are Saying About Immunocore Hldgs Stock
4 Analysts Assess Geron: What You Need To Know
Where Recursion Pharmaceuticals Stands With Analysts
8 Analysts Have This To Say About Nurix Therapeutics
Analyst Expectations For Immunocore Hldgs's Future
Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside
Needham initiated a Buy rating for Absci (ABSI), noting its AI-powered drug discovery platforms, strategic partnerships, and $9 price target.
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
What 14 Analyst Ratings Have To Say About Sarepta Therapeutics
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2025 Benzinga | All Rights Reserved